Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

• Egile Nagusiak: Francisco Marin (Egilea), Marcelo Sanmartin Fernandez (Egilea), Gonzalo Baron-Esquivias (Egilea), Vivencio Barrios (Egilea), Inaki Lekuona (Egilea), Alejandro I Perez-Cabeza (Egilea), Jaime Masjuan (Egilea), Esther Recalde del Vigo (Egilea), Jose Manuel Vazquez Rodriguez (Egilea), Roman Freixa-Pamias (Egilea), Vanessa Roldan Schilling (Egilea), Fernando Arribas (Egilea), Carles Rafols Priu (Egilea), Manuel Anguita Sanchez (Egilea)
• Formatua: Liburua
• Argitaratua: Becaris Publishing Limited, 2023-02-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Aim: It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients. This study was aimed to analyze the impact of cardiovascular disease on this population. Materials & methods: EMIR was a multicenter, prospective study, including 1433 AF patients taking ri...